Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment

BACKGROUND: Recombinant human growth hormone (rhGH) is approved in Europe as a treatment for short children born small for gestational age (SGA) since 2003. However, no study evaluated the prevalence of SGA children with short stature who qualify for rhGH in Europe so far. This study aimed to invest...

詳細記述

保存先:
書誌詳細
出版年:Ital J Pediatr
主要な著者: Tamaro, Gianluca, Pizzul, Mariagrazia, Gaeta, Giuliana, Servello, Raffaella, Trevisan, Marina, Böhm, Patricia, Materassi, Paola Manera Ada, Macaluso, Anna, Valentini, Denis, Pellegrin, Maria Chiara, Barbi, Egidio, Tornese, Gianluca
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2021
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://ncbi.nlm.nih.gov/pubmed/33794966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-021-01026-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料